Kohn & Associates, since its founding, has been internationally recognized as one of the foremost IP firms specializing in biotechnology. As true pioneers in the field, Kohn & Associates has been recognized by the National Institutes of Health as one of the top twelve (12) firms worldwide specializing in biotechnology patent prosecution. These rankings were the product not only of our technical expertise in technologies and intellectual property issues, but also based on our proposal for partnering with the NIH in its case management approach.
Our biotech clients span the full spectrum of innovative settings: from prestigious research universities and institutions, to Fortune 500 ® corporations, to start-ups. We have represented inventors considered pioneers in their respective scientific disciplines, and successfully prosecuted applications for cutting-edge therapies, treatments, and procedures.
Our large biotechnology practice encompasses a broad range of established and emerging scientific technologies and approaches, including DNA, RNA, protein and antibody therapeutics and diagnostics, plant biotechnology, industrial technology and research platforms, nanotechnology, and interdisciplinary inventions.
Key to success in the intellectual property arena is the ability to align business goals and patent strategy to protect commercial products, maximize the value of IP portfolios for out-licensing, navigate through competitors’ IP, and leverage IP for new business opportunities. The field of biotechnology poses unique problems for companies by virtue of science that is sometimes unpredictable and product development cycles that may take many years. We understand the development cycle and are able to work with clients to devise successful strategies and build U.S. and foreign patent portfolios to protect commercial products and processes. We have procured, enforced and/or defended patents relating to a number of billion-dollar products.
Additionally, our work with universities and other major research institutions, start-ups and established publicly or privately held firms, including Fortune 500 companies, provides us with a 360-degree perspective and an uncommon view of new ideas, applications and opportunities for our clients.
We understand that clients have different needs and objectives depending on their stage of growth and development, and we help them to meet their goals at every stage.
Our relationships with academia and industry, as well as our experience with executing IP strategies for both early stage product candidates and established marketed products, positions us as a cornerstone for the bridge between innovation and commercial success.